【Superior potency】
- Superior potency compared to Pirfenidone,15-fold increase in TNF-α inhibition, and good bioactivity in TGF-β
- PhII blind data show good efficacy in clinical
【Better Safety】
- Large Safety Window
- Good safety & tolerability in clinical PhIa, PhIb, and ongoing PhII
- Long-term GLP Tox: 26- week rat GLP study completed, 39-week in dog completed, both support long-term clinical usage with ideal therapeutic window
【Favorable Administration】
- 150mg bid，300mg daily
【Lower Risk for Photo-Tox】
- No Photo-Tox concern in non-clinical and clinical
【CMC】
- API process ready & scalable for NDA, Drug product tablet formulation and process well developed
- Lower COGs
【IP Protection】
- Patents secured till 2037+
【Rights for licensing】
- Ex-China rights or Global rights
【Contact info】
- If interested, please contact DrugTimes BD Team at BD@drugtimes.cn
发布者：DrugTimes001，转载请首先联系contact@drugtimes.cn获得授权
为好文打赏 支持药时代 共创新未来！ 